Overweight or Obesity
Conditions
Brief summary
This is a randomized, double-blind, placebo-controlled phase 1 clinical study evaluating the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of multiple ascending doses of IBI3032 in participants with overweight or obesity. It is a multiple ascending dose study in participants with overweight or obesity during the 4-week treatment period.
Interventions
DRUGIBI3032
IBI3032. Method of administration: oral, fasted administration.
DRUGplacebo
Placebo (without active ingredients). Method of administration: oral, fasted administration.
Sponsors
Innovent Biologics Technology Limited (Shanghai R&D Center)
Study design
Allocation
RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
Yes
Inclusion criteria
* Healthy male or females, as determined by medical history * Have safety laboratory results within normal reference ranges
Exclusion criteria
* Have known allergies toIBI3032， glucagon-like peptide-1 (GLP-1) analogs, related compounds * Abnormal electrocardiogram (ECG) at screening * Significant history of or current cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological or neurological disorders.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants with One Serious Adverse Event(s) Considered by the Investigator to be Related to Study Drug | Baseline up to Day 43 | A summary of SAEs regardless of causality, will be reported in the Reported Adverse Events module |
| Number of Participants with More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug | Baseline up to Day 43 | A summary of other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module |
| Number of Participants with adverse events (AEs) | An adverse event (AE) is defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. | Baseline up to Day 43 |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| clearance (CL) of IBI3032 | Day 1 and Day 28：Predose up to 24 hours postdose. Day 8, Day 15 and Day 22：Predose up to 4 hours postdose. | To evaluate the pharmacokinetic (PK) characteristics of a single dose of IBI3032 in healthy participants. |
| Under the Serum Concentration-time Curve (AUC) of IBI3032 | Day 1 and Day 28：Predose up to 24 hours postdose. Day 8, Day 15 and Day 22：Predose up to 4 hours postdose. | To evaluate the pharmacokinetic (PK) characteristics of a single dose of IBI3032 in healthy participants. |
| elimination half-life (T1/2) of IBI3032 | Day 1 and Day 28：Predose up to 24 hours postdose. Day 8, Day 15 and Day 22：Predose up to 4 hours postdose. | To evaluate the pharmacokinetic (PK) characteristics of a single dose of IBI3032 in healthy participants. |
| apparent volume of distribution (V) of IBI3032 | Day 1 and Day 28：Predose up to 24 hours postdose. Day 8, Day 15 and Day 22：Predose up to 4 hours postdose. | To evaluate the pharmacokinetic (PK) characteristics of a single dose of IBI3032 in healthy participants. |
| maximum concentration (Cmax) of IBI3032 | Day 1 and Day 28：Predose up to 24 hours postdose. Day 8, Day 15 and Day 22：Predose up to 4 hours postdose. | To evaluate the pharmacokinetic (PK) characteristics of a single dose of IBI3032 in healthy participants. |
| time to maximum concentration (Tmax) of IBI3032 | Day 1 and Day 28：Predose up to 24 hours postdose. Day 8, Day 15 and Day 22：Predose up to 4 hours postdose. | To evaluate the pharmacokinetic (PK) characteristics of a single dose of IBI3032 in healthy participants. |
Countries
China
Outcome results
None listed